Generic Name: liraglutide
Brand Name: Saxenda
Manufacturer: Novo Nordisk Canada Inc.
Therapeutic Area: Chronic weight management in adults
Indications: Saxenda® (liraglutide) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: ≥30 kg/m2 or greater (obese), or ≥27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, or dyslipidemia) and who have failed a previous weight management intervention.
Manufacturer Requested Reimbursement Criteria1: An adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients who have been diagnosed with: Obesity (BMI ≥30 kg/m2) AND prediabetes, or Overweight (BMI ≥27 kg/m2 and ≥30 kg/m2) with one or more weight-related comorbidity AND prediabetes.
Submission Type: Initial
NOC Status at Filing: Post NOC
Project Status: Active
Companion Diagnostics: No
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient/clinician input open||November 26, 2020|
|Call for patient/clinician input closed||January 22, 2021|
- Patient input submission received from Diabetes Canada, Gastrointestinal Society and Obesity Canada
|Submission received||December 23, 2020|
|Submission accepted||January 14, 2021|
|Review initiated||January 15, 2021|
|Draft CADTH review report(s) provided to sponsor for comment||April 09, 2021|
|Deadline for sponsors comments||April 20, 2021|
|CADTH responses on draft review report(s) provided to sponsor||May 07, 2021|
|Expert committee meeting (initial)||May 19, 2021|
|Draft recommendation issued to sponsor||June 01, 2021
June 03, 2021
|Draft recommendation posted for stakeholder feedback||-|